EP4473969A1 — Oral solid preparation
Assigned to Kissei Pharmaceutical Co Ltd · Expires 2024-12-11 · 1y expired
What this patent protects
An object of the present invention is to provide an oral solid preparation having a rapid dissolution property even when the content of Linzagolix or a pharmacologically acceptable salt thereof in the oral solid preparation varies over a wide range.The present invention relates t…
USPTO Abstract
An object of the present invention is to provide an oral solid preparation having a rapid dissolution property even when the content of Linzagolix or a pharmacologically acceptable salt thereof in the oral solid preparation varies over a wide range.The present invention relates to an oral solid preparation comprising Linzagolix or a pharmacologically acceptable salt thereof; crystalline cellulose; low-substituted hydroxypropyl cellulose; and one or more disintegrants selected from the group consisting of carmellose sodium, carmellose calcium and croscarmellose sodium, and the like.
Drugs covered by this patent
- Orgovyx (relugolix) · MYOVANT SCIENCES
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.